- Home
- EVER vs ETNB Comparison
EVER vs ETNB Comparison
Compare EVER & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVER
- ETNB
- Stock Information
- Founded
- EVER 2008
- ETNB 2018
- Country
- EVER United States
- ETNB United States
- Employees
- EVER N/A
- ETNB N/A
- Industry
- EVER Computer Software: Programming Data Processing
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- EVER Technology
- ETNB Health Care
- Exchange
- EVER Nasdaq
- ETNB Nasdaq
- Market Cap
- EVER 960.3M
- ETNB 1.0B
- IPO Year
- EVER 2018
- ETNB 2019
- Fundamental
- Price
- EVER $23.05
- ETNB $7.80
- Analyst Decision
- EVER Strong Buy
- ETNB Strong Buy
- Analyst Count
- EVER 6
- ETNB 9
- Target Price
- EVER $32.50
- ETNB $27.25
- AVG Volume (30 Days)
- EVER 664.5K
- ETNB 1.5M
- Earning Date
- EVER 05-05-2025
- ETNB 05-01-2025
- Dividend Yield
- EVER N/A
- ETNB N/A
- EPS Growth
- EVER N/A
- ETNB N/A
- EPS
- EVER 1.03
- ETNB N/A
- Revenue
- EVER $575,757,000.00
- ETNB N/A
- Revenue This Year
- EVER $27.51
- ETNB N/A
- Revenue Next Year
- EVER $11.88
- ETNB N/A
- P/E Ratio
- EVER $22.40
- ETNB N/A
- Revenue Growth
- EVER 113.43
- ETNB N/A
- 52 Week Low
- EVER $16.63
- ETNB $4.16
- 52 Week High
- EVER $30.03
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- EVER 49.57
- ETNB 55.22
- Support Level
- EVER $22.34
- ETNB $7.40
- Resistance Level
- EVER $27.05
- ETNB $8.92
- Average True Range (ATR)
- EVER 1.21
- ETNB 0.54
- MACD
- EVER 0.07
- ETNB 0.14
- Stochastic Oscillator
- EVER 36.55
- ETNB 59.74
About EVER EverQuote Inc.
EverQuote Inc is engaged in the business activity of offering an online marketplace for insurance shopping, connecting consumers with insurance provider customers, which includes both carriers and agents. The online marketplace offers consumers to find relevant insurance quotes based on car insurance, home insurance, and life insurance. The platform of the company is driven by data science. The firm's data and technology platform match and connects consumers seeking to purchase insurance with relevant options from its broad direct network of insurance providers. It derives a majority of revenue from Direct channels.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).